RU2266129C2 - Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации - Google Patents

Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации Download PDF

Info

Publication number
RU2266129C2
RU2266129C2 RU2003131695/14A RU2003131695A RU2266129C2 RU 2266129 C2 RU2266129 C2 RU 2266129C2 RU 2003131695/14 A RU2003131695/14 A RU 2003131695/14A RU 2003131695 A RU2003131695 A RU 2003131695A RU 2266129 C2 RU2266129 C2 RU 2266129C2
Authority
RU
Russia
Prior art keywords
peptide
prosaposin
neuropathic pain
glu
leu
Prior art date
Application number
RU2003131695/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2003131695A (ru
Inventor
Джон С. О`БРАЙЕН (US)
Джон С. О`БРАЙЕН
Original Assignee
Риджентс оф Дзе Юниверсити оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Риджентс оф Дзе Юниверсити оф Калифорния filed Critical Риджентс оф Дзе Юниверсити оф Калифорния
Publication of RU2003131695A publication Critical patent/RU2003131695A/ru
Application granted granted Critical
Publication of RU2266129C2 publication Critical patent/RU2266129C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2003131695/14A 1996-03-05 1997-03-05 Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации RU2266129C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/611,307 US6271196B1 (en) 1996-03-05 1996-03-05 Methods of alleviating neuropathic pain using prosaposin-derived peptides
US08/611,307 1996-03-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU98118091/04A Division RU2223969C2 (ru) 1996-03-05 1997-03-05 Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина

Publications (2)

Publication Number Publication Date
RU2003131695A RU2003131695A (ru) 2005-04-10
RU2266129C2 true RU2266129C2 (ru) 2005-12-20

Family

ID=24448513

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2003131695/14A RU2266129C2 (ru) 1996-03-05 1997-03-05 Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации
RU98118091/04A RU2223969C2 (ru) 1996-03-05 1997-03-05 Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU98118091/04A RU2223969C2 (ru) 1996-03-05 1997-03-05 Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина

Country Status (16)

Country Link
US (2) US6271196B1 (enExample)
EP (1) EP0929569B1 (enExample)
JP (1) JP4138006B2 (enExample)
KR (1) KR100507715B1 (enExample)
AT (1) ATE340187T1 (enExample)
AU (1) AU734566B2 (enExample)
CA (1) CA2248139C (enExample)
CZ (1) CZ297384B6 (enExample)
DE (1) DE69736712T2 (enExample)
IL (1) IL126082A0 (enExample)
NO (1) NO984093L (enExample)
NZ (1) NZ331757A (enExample)
PL (1) PL187917B1 (enExample)
RU (2) RU2266129C2 (enExample)
SK (1) SK122898A3 (enExample)
WO (1) WO1997032895A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2345786C2 (ru) * 2007-02-27 2009-02-10 Андрей Евгеньевич Кульчиков Способ лечения непрерывно-прогредиентных дегенеративных и демиелинизирующих заболеваний
RU2561582C2 (ru) * 2010-11-19 2015-08-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения
RU2669692C1 (ru) * 2017-08-14 2018-10-15 Павел Андреевич Канаев Способ получения комплекса биологически активных пептидов обладающих нейротропной активностью
RU2767199C1 (ru) * 2018-03-23 2022-03-16 Биксион Фармасьютикалз Инк. Фармацевтические композиции сапозина с и способы лечения рака
RU2831429C2 (ru) * 2019-05-21 2024-12-06 Сосьете Де Продюи Нестле С.А. Пищевой бутират и его применение

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US6849602B1 (en) * 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
JP2001524944A (ja) * 1997-03-05 2001-12-04 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 神経障害性疼痛の緩和方法
WO1998039357A1 (en) * 1997-03-05 1998-09-11 The Regents Of The University Of California Method of alleviating neuropathic pain
CA2284105A1 (en) * 1997-03-24 1998-10-01 John S. O'brien Synthetic saposin c-derived neurotrophic peptides
CA2304108A1 (en) * 1997-09-09 1999-03-18 The Regents Of The University Of California Inhibition of apoptotis using prosaposin receptor agonists
US6458357B1 (en) * 1997-09-09 2002-10-01 Myelos Corporation Retro-inverso neurotrophic and analgesic peptides
CZ2001655A3 (cs) * 1998-08-28 2001-11-14 Myelos Corporation Cyklický peptid, prostředek, způsob indukce myelinizace, způsob potlačení degenerace neuronů a způsob léčby
US20020028783A1 (en) * 1999-09-09 2002-03-07 O'brien John S. Method of stimulating prosaposin receptor activity
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
WO2000058359A1 (en) * 1999-03-30 2000-10-05 Myelos Corporation Retro-inverso prosaposin-derived peptides and use thereof
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7109168B1 (en) 2000-06-16 2006-09-19 Myelos Corporation Retro-inverso peptides derived from leukemia inhibitory factor
US7135461B1 (en) 2000-06-16 2006-11-14 Myelos Corporation Retro-inverso peptides derived from interleukin-6
AU5496500A (en) * 1999-06-16 2001-01-02 Myelos Corporation Retro-inverso peptides derived from interleukin-3
IL147095A0 (en) * 1999-06-16 2002-08-14 Myelos Corp Retro-inverso peptides derived from leukemia inhibitory factor
CA2376479A1 (en) * 1999-06-16 2000-12-21 David E. Wright Retro-inverso peptides derived from interleukin-6
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20040170955A1 (en) * 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20060287240A1 (en) * 2001-03-09 2006-12-21 O'brien John S Method of stimulating prosaposin receptor activity
US20040176290A1 (en) * 2001-07-18 2004-09-09 Renata Pasqualini Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
AU2003259846A1 (en) * 2002-08-16 2004-03-03 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US7166691B2 (en) * 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
WO2004084930A1 (en) * 2003-03-26 2004-10-07 Develogen Aktiengesellschaft Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
EP1613321A2 (en) * 2003-03-28 2006-01-11 Acadia Pharmaceuticals Inc. Muscarinic m1 receptor agonists for pain management
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP1736481A1 (en) * 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
RU2317829C2 (ru) * 2005-10-05 2008-02-27 Федеральное государственное учреждение науки "Екатеринбургский медицинский научный центр профилактики и охраны здоровья рабочих промпредприятий" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ лечения мононевропатий верхних конечностей
US7964585B2 (en) * 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
KR20180123731A (ko) 2008-01-22 2018-11-19 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
WO2012115185A1 (ja) * 2011-02-23 2012-08-30 北海道公立大学法人札幌医科大学 疼痛を治療、改善、または予防するための組成物
SG11202007887VA (en) 2018-03-29 2020-09-29 Lateral IP Pty Ltd Cyclic peptides and uses thereof
EP4274657A4 (en) * 2021-01-09 2024-12-11 Bexion Pharmaceuticals, Inc. METHODS FOR REDUCING NEUROPATHY AND NEUROPATHIC SYMPTOMS AND TREATING CANCER

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
RU2037498C1 (ru) * 1989-04-28 1995-06-19 Пфайзер Инк. Способ получения полипептидов

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750197D1 (de) 1986-04-22 1994-08-18 Salk Inst For Biological Studi Antagonisten des Fibroblasten-Wachstumsfaktors.
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
RU2007417C1 (ru) * 1991-06-21 1994-02-15 Российский государственный медицинский университет Способ получения плацентарного протеина
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5534495A (en) * 1993-05-25 1996-07-09 Advanced Peptides And Biotechnology Sciences Treatment of non-HIV neuropathic pain syndromes
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
CA2176708A1 (en) * 1993-11-15 1995-05-26 Christopher A. Maack Method of treating neurological disorders
WO1998039357A1 (en) * 1997-03-05 1998-09-11 The Regents Of The University Of California Method of alleviating neuropathic pain
CA2284105A1 (en) * 1997-03-24 1998-10-01 John S. O'brien Synthetic saposin c-derived neurotrophic peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2037498C1 (ru) * 1989-04-28 1995-06-19 Пфайзер Инк. Способ получения полипептидов
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2345786C2 (ru) * 2007-02-27 2009-02-10 Андрей Евгеньевич Кульчиков Способ лечения непрерывно-прогредиентных дегенеративных и демиелинизирующих заболеваний
RU2561582C2 (ru) * 2010-11-19 2015-08-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения
RU2669692C1 (ru) * 2017-08-14 2018-10-15 Павел Андреевич Канаев Способ получения комплекса биологически активных пептидов обладающих нейротропной активностью
RU2767199C1 (ru) * 2018-03-23 2022-03-16 Биксион Фармасьютикалз Инк. Фармацевтические композиции сапозина с и способы лечения рака
US11590227B2 (en) 2018-03-23 2023-02-28 Bexion Pharmaceuticals, Inc. Saposin C pharmaceutical compositions and methods of treating cancer
US12194099B2 (en) 2018-03-23 2025-01-14 Bexion Pharmaceuticals Inc. Saposin C pharmaceutical compositions and methods of treating cancer
RU2831429C2 (ru) * 2019-05-21 2024-12-06 Сосьете Де Продюи Нестле С.А. Пищевой бутират и его применение

Also Published As

Publication number Publication date
ATE340187T1 (de) 2006-10-15
RU2003131695A (ru) 2005-04-10
SK122898A3 (en) 2000-02-14
WO1997032895A1 (en) 1997-09-12
CA2248139C (en) 2004-05-18
NZ331757A (en) 1999-10-28
PL328701A1 (en) 1999-02-15
KR19990087686A (ko) 1999-12-27
DE69736712D1 (de) 2006-11-02
US6268347B1 (en) 2001-07-31
AU734566B2 (en) 2001-06-14
RU2223969C2 (ru) 2004-02-20
PL187917B1 (pl) 2004-11-30
CA2248139A1 (en) 1997-09-12
CZ297384B6 (cs) 2006-11-15
KR100507715B1 (ko) 2006-05-26
CZ283998A3 (cs) 1999-05-12
IL126082A0 (en) 1999-05-09
JP2000506853A (ja) 2000-06-06
DE69736712T2 (de) 2007-09-13
EP0929569A1 (en) 1999-07-21
EP0929569B1 (en) 2006-09-20
NO984093D0 (no) 1998-09-04
US6271196B1 (en) 2001-08-07
EP0929569A4 (en) 2000-08-23
JP4138006B2 (ja) 2008-08-20
NO984093L (no) 1998-11-04
AU2328697A (en) 1997-09-22

Similar Documents

Publication Publication Date Title
RU2266129C2 (ru) Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации
AU751034B2 (en) Cyclic prosaposin-derived peptides and uses thereof
JPH09503999A (ja) 治療剤としてのプロサポシンおよびサイトカイン由来ペプチド
JPH11505548A (ja) グリア細胞系由来神経栄養因子（ｇｄｎｆ）蛋白産物を用いたハンチントン病の治療方法
US6849602B1 (en) Compositions for alleviating neuropathic pain with prosaposin receptor agonists
EP0979238A1 (en) Method of alleviating neuropathic pain
JP2001527402A (ja) Ｎｇｆ変異体
AU2002300005B2 (en) Method of alleviating neuropathic pain
AU4267297A (en) Method of alleviating neuropathic pain
WO1998042746A2 (en) Synthetic saposin c-derived neurotrophic peptides
MXPA98007245A (en) Methods to alleviate neuropathic pain using peptides derived from prosapos
CN1224430A (zh) 利用prosaposin衍生多肽缓解神经性疼痛的方法
MXPA01001966A (en) Cyclic prosaposin-derived peptides and uses thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080306